Short answer
Stoke Therapeutics, Inc. (STOK) filed its Q2 2026 10-Q quarterly report on Aug 3, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $9M (down 32.5% year over year) with net income of −$62M.
Q2 2026 key financials · XBRL
- Revenue
- $9M
- −32.5% YoY · +49.7% QoQ
- Net income
- −$62M
- −162.4% YoY · −23.2% QoQ
- Operating margin
- -701.7%
- EPS (diluted)
- −$0.94
- −135.0% YoY · −19.0% QoQ
Source: XBRL data from the Stoke Therapeutics, Inc. (STOK) Q2 2026 10-Q on SEC EDGAR. USD.
Stoke Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly emphasized clinical risk: STK-002 entered Phase 1 OSPREY dosing in February 2026, increasing exposure to early-stage trial failure
- Regulatory risk: Supreme Court’s June 2024 Chevron reversal may increase challenges to FDA regulations and approval requirements
- Near-term operational risk: Hospital staffing shortages may delay trial enrollment, site visits, evaluations, or patient dosing
- Market risk: Dravet syndrome incidence approximately one in 15,600 births, limiting enrollment and commercial-market size
- Financial risk: Continued operating losses require additional funding before potential product sales support profitability
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Stoke Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.